Telefônica Brasil Reports Strong 4Q25 Results with Double-Digit FCF Growth and R$6.99 Billion Shareholder Remuneration
VIV sits 91% above its 52-week low of $8.09.
Summary
Telefônica Brasil delivered robust fourth-quarter 2025 results, featuring significant revenue and EBITDA growth, a 111.9% increase in Free Cash Flow, and approved R$6.99 billion in shareholder remuneration for 2026.
Key Events · Earnings and Guidance · VIV
-
Strong 4Q25 Financial Performance
Net revenue grew +7.1% YoY to R$15.6 billion, with reported EBITDA up +8.1% YoY to R$6.7 billion.
-
Exceptional Free Cash Flow Growth
Free Cash Flow surged +111.9% YoY to R$2.29 billion in 4Q25, driven by strong EBITDA and reduced Capex.
-
Significant Shareholder Remuneration
Approved R$6.99 billion for 2026, comprising a R$4.0 billion capital reduction and R$2.99 billion in interest on capital, reaffirming a commitment to over 100% net income payout.
-
Robust Operational Growth
Postpaid accesses increased +6.5% YoY, and Fiber-to-the-Home (FTTH) accesses grew +12.0% YoY, alongside expanded 5G coverage.
Analysis · VIV · Technology
The company demonstrated strong operational execution in 4Q25, with solid growth across key segments like postpaid, fiber-to-the-home (FTTH), and B2B digital services. The substantial increase in Free Cash Flow, coupled with a reduction in Capex, highlights improved efficiency and cash generation. The approved R$6.99 billion in shareholder remuneration for 2026, including a R$4.0 billion capital reduction and R$2.99 billion in interest on capital, underscores management's commitment to returning value to investors and maintaining a payout ratio of at least 100% of net income. These results position Telefônica Brasil favorably, indicating healthy business momentum and a strong financial outlook.
At the time of this filing, VIV was trading at $15.45 on NYSE in the Technology sector, with a market capitalization of approximately $25.2B. The 52-week trading range was $8.09 to $16.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.